Top

Current Oncology Reports

Published in:

01-08-2021 | Ovarian Cancer | Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Progress in Gynecologic Cancers with Antibody Drug Conjugates

Authors: David M. O’Malley, Corinne A. Calo

Published in: Current Oncology Reports | Issue 8/2021

Abstract

Purpose of review

This article provides a comprehensive review of antibody-drug conjugates (ADCs) under investigation in gynecologic cancers. The structure and function of ADCs are reviewed with a focus on clinical benefit as well as toxicity profiles.

Recent findings

Several ADCs with various target antigens have been investigated in ovarian, cervical, and endometrial cancer. ADCs have consistently demonstrated favorable safety/tolerability profiles both as monotherapy and in combination therapy. In ovarian cancer, response rates have ranged from 9 to 46% for monotherapy with response rates as high as 83% in combination therapy. In patients with cervical cancer with progressive disease despite doublet therapy and bevacizumab, response rates as high as 24% have been observed.

Summary

ADCs represent a rapidly evolving field of targeted therapy which have demonstrated notable clinical benefit both as monotherapy but also in combination therapy with an overall favorable toxicity profile. With continued refinement of the target biomarkers utilized, improved clinical benefit is likely to be observed.

Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54. https://doi.org/10.1200/JCO.2001.19.13.3244.CrossRefPubMed

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/NEJMoa1209124.CrossRefPubMedPubMedCentral

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. https://doi.org/10.1056/NEJMoa1814017.CrossRef

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510.CrossRefPubMed

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51. https://doi.org/10.1056/NEJMoa1814213.CrossRefPubMed

Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/jco.19.01140.CrossRefPubMedPubMedCentral

Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov. 2018;17(3):197–223. https://doi.org/10.1038/nrd.2017.227.CrossRefPubMed

Elias DJ, Hirschowitz L, Kline LE, Kroener JF, Dillman RO, Walker LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 1990;50(13):4154–9.PubMed

Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478–84. https://doi.org/10.1200/jco.1999.17.2.478.CrossRefPubMed

10.

Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13–21. https://doi.org/10.4161/mabs.22854.CrossRefPubMedPubMedCentral

11.

Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, et al. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology. 2018;7(3):e1395127. https://doi.org/10.1080/2162402x.2017.1395127.CrossRefPubMed

12.

Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659–71. https://doi.org/10.1080/19420862.2016.1156829.CrossRefPubMedPubMedCentral

13.

Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111(6):538–49. https://doi.org/10.1093/jnci/djz035.CrossRefPubMed

14.

Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019;153(3):694–702. https://doi.org/10.1016/j.ygyno.2019.03.245.CrossRefPubMed

15.

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70. https://doi.org/10.1158/1078-0432.CCR-04-0789.CrossRefPubMed

16.

Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, et al. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 2017;28(5):1371–81. https://doi.org/10.1021/acs.bioconjchem.7b00062.CrossRefPubMed

17.

Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975;189(4207):1002–5. https://doi.org/10.1126/science.1241159.CrossRefPubMed

18.

Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–26. https://doi.org/10.1016/j.ygyno.2007.11.020.CrossRefPubMedPubMedCentral

19.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018;14(2):123–36. https://doi.org/10.2217/fon-2017-0379.CrossRefPubMed

20.

Brown Jones M, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, et al. Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer. 2008;123(7):1699–703. https://doi.org/10.1002/ijc.23686.CrossRefPubMed

21.

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–7. https://doi.org/10.1002/cncr.30736.CrossRefPubMed

22.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112–8. https://doi.org/10.1200/JCO.2016.69.9538.CrossRefPubMed

23.

Moore K, Matulonis U, O'Malley D, Konner J, Martin L, Perez R, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): activity and safety analyses in phase I pooled expansion cohorts. Journal of Clinical Oncology 2017. p. 5547.

24.

Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, et al. FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018;14(17):1669–78. https://doi.org/10.2217/fon-2017-0646.CrossRefPubMed

25.

Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. FORWARD I (GOG3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients with platinum-resistant ovarian cancer (PROC). Ann Oncol. 2019;30:v403–34.CrossRef

26.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151(1):46–52. https://doi.org/10.1016/j.ygyno.2018.07.017.CrossRefPubMed

27.

O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157:379–85. https://doi.org/10.1016/j.ygyno.2020.01.037.CrossRefPubMed

28.

Gilbert L, Oaknin A, Matulonis U, Mantia-Smaldone G, Lim P, Castro C, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevaciziumab in patients with platinum-agnostic ovarian cancer. J Clin Oncol. 2020;38:6004.CrossRef

29.

O'Malley D, Richardson D, Vergote I, Gilbert L, Martin L, Mantia-Smaldone G, et al. Mirvetuximab soravtaninse, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: initial results from a phase 1b study in patients with ovarian cancer. Ann Oncol. 2019:v403–34.

30.

Matulonis U, Moore K, Martin L, Vergote I, Castro C, Gilbert L, et al. Mirvetuximab soravtaninse, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), with pembrolizumab, in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study. Abstracts Gynaecological Cancers: Annals of Oncology; 2018.

31.

Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38(16):1824–35. https://doi.org/10.1200/jco.19.02085.CrossRefPubMedPubMedCentral

32.

Bulat I, Moore K, Haceatrean A, Chung J, Rajagopalan P, Xia C, et al. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2018;36:5571.CrossRef

33.

Coleman R, Lorusso D, Gennigens C, Gonzalez-Martin A, Randall L, Cibula D, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. Ann Oncol. 2020:S1142–S215.

34.

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020;26(6):1220–8. https://doi.org/10.1158/1078-0432.ccr-19-2962.CrossRefPubMed

35.

de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(3):383–93. https://doi.org/10.1016/s1470-2045(18)30859-3.CrossRefPubMed

36.

Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29(4):917–23. https://doi.org/10.1093/annonc/mdy023.CrossRefPubMed

37.

Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, et al. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020;158(3):631–9. https://doi.org/10.1016/j.ygyno.2020.05.039.CrossRefPubMed

38.

Lim SI. Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic. Drug Discov Today. 2020;25(1):168–76. https://doi.org/10.1016/j.drudis.2019.10.002.CrossRefPubMed

39.

Li X, Abrahams C, Zhou S, Krimm S, Henningsen R, Stephenson H, et al. Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer. Cancer Res 2018. p. 1782.

40.

Naumann R, Braiteh F, Diaz J, Hamilton E, Diab S, Schilder R, et al. Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRalpha) antibody drug conjugate (ADC), in patients with advanced, platinum-resistant/refractory epithelial ovarian cancer. IGSC Annual Meeting 2020.

41.

Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Shimomura A, Tamura K, et al. First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors. J Clin Oncol. 2019;37:5544.CrossRef

42.

Tolcher A, Ulahannan S, Papadopoulos K, Edenfield W, Matulonis U, Burns T, et al. Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients with solid tumors likely to express NaPi2b. J Clin Oncol. 2019;37:3010.CrossRef

43.

Hamilton E, Barve M, Tolcher A, Buscema J, Papadopoulos K, Zarwan C, et al. Safety and efficacy of XMT-1536 in ovarian cancer: a subgroup analysis from the Phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate. European Society of Medical Oncology (ESMO) Virtual Congress 2020.

44.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(3):439–47. https://doi.org/10.1158/1535-7163.mct-15-0693.CrossRefPubMed

45.

Clarke J, Chu S, Siu L, Machiels J, Markman B, Heinhuis K, et al. BMS-986128, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced tumors. Molecular Cancer Therapeutics 2019. B057.

46.

Moore K, Hamilton E, Burris H, Barroilhet L, Gutierrez M, Wang J, et al. Abstract CT036: targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a phase I expansion study. Cancer Res 2018. CT036.

47.

Calo CA, O'Malley DM. Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opin Biol Ther. 2020:1–13. https://doi.org/10.1080/14712598.2020.1776253.

48.

Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604. https://doi.org/10.1089/jop.2015.0064.CrossRefPubMedPubMedCentral

49.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31(35):4400–6. https://doi.org/10.1200/jco.2013.49.7685.CrossRefPubMed

Title: Progress in Gynecologic Cancers with Antibody Drug Conjugates
Authors: David M. O’Malley
Corinne A. Calo
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Ovarian Cancer
Cervical Cancer
Ovarian Cancer
Cervical Cancer
Gynecologic Cancer
Targeted Therapy
Bevacizumab
Endometrial Cancer
Endometrial Cancer
Published in: Current Oncology Reports / Issue 8/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-021-01080-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2021

ROS1 Targeted Therapies: Current Status

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic

The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities

Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

Prostate Cancer Immunotherapy—Finally in From the Cold?

DNA Repair Mechanisms and Therapeutic Targets in Glioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer